应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GH Guardant Health Inc.
已收盘 03-20 16:00:00 EDT
85.18
-3.90
-4.38%
盘后
86.84
+1.66
+1.95%
19:59 EDT
最高
89.11
最低
84.42
成交量
240.12万
今开
88.74
昨收
89.08
日振幅
5.27%
总市值
111.73亿
流通市值
107.33亿
总股本
1.31亿
成交额
2.06亿
换手率
1.91%
流通股本
1.26亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Guardant Health携手宏利在亚洲多市场推出Shield多癌种检测产品
美股速递 · 03-16
Guardant Health携手宏利在亚洲多市场推出Shield多癌种检测产品
宏利金融与Guardant Health达成独家合作,将Shield多癌种早筛检测引入亚洲市场
美股速递 · 03-16
宏利金融与Guardant Health达成独家合作,将Shield多癌种早筛检测引入亚洲市场
财报前瞻|Guardant Health Inc.营收预计强劲增长,机构观点偏多
财报Agent · 02-12
财报前瞻|Guardant Health Inc.营收预计强劲增长,机构观点偏多
Guardant Health, Inc.涨2.82% 股价突破100美元大关
市场透视 · 02-06
Guardant Health, Inc.涨2.82% 股价突破100美元大关
维升药业隆培生长激素获批:1年长高11厘米,百亿市场格局生变
21世纪经济报道 · 01-26
维升药业隆培生长激素获批:1年长高11厘米,百亿市场格局生变
Guardant Health公司Guardant360® Cdx获FDA批准 作为Braftovi®(Encorafenib)联合疗法在BRAF V600E突变转移性结直肠癌患者中的伴随诊断
美股速递 · 01-22
Guardant Health公司Guardant360® Cdx获FDA批准 作为Braftovi®(Encorafenib)联合疗法在BRAF V600E突变转移性结直肠癌患者中的伴随诊断
Guardant Health与Trial Library达成合作,提升美国癌症临床试验的可及性
美股速递 · 2025-12-11
Guardant Health与Trial Library达成合作,提升美国癌症临床试验的可及性
Guardant Health 拟发行 3 亿美元可转换高级票据,到期时间为2033年
投资观察 · 2025-11-20
Guardant Health 拟发行 3 亿美元可转换高级票据,到期时间为2033年
Guardant Health:肿瘤信号上升使疾病进展早至18个月,平均提前时间为2.3个月
美股速递 · 2025-11-06
Guardant Health:肿瘤信号上升使疾病进展早至18个月,平均提前时间为2.3个月
Guardant Health:肿瘤信号减少超过98%的患者获得了显著益处
美股速递 · 2025-11-06
Guardant Health:肿瘤信号减少超过98%的患者获得了显著益处
异动解读 | Guardant Health股价盘中大跌8.77%,6.5亿美元融资计划引发投资者担忧
异动解读 · 2025-11-05
异动解读 | Guardant Health股价盘中大跌8.77%,6.5亿美元融资计划引发投资者担忧
异动解读 | Guardant Health股价盘前大跌6.15%,新股发行和可转债计划引发投资者担忧
异动解读 · 2025-11-05
异动解读 | Guardant Health股价盘前大跌6.15%,新股发行和可转债计划引发投资者担忧
异动解读 | Guardant Health夜盘大跌7.59%,新股和可转债发行计划引发投资者担忧
异动解读 · 2025-11-05
异动解读 | Guardant Health夜盘大跌7.59%,新股和可转债发行计划引发投资者担忧
异动解读 | Guardant Health盘后大跌8.55%,拟发行新股和可转债
异动解读 · 2025-11-05
异动解读 | Guardant Health盘后大跌8.55%,拟发行新股和可转债
异动解读 | 盘中飙升27.45%,Guardant Health财报超预期提振投资者信心
异动解读 · 2025-10-30
异动解读 | 盘中飙升27.45%,Guardant Health财报超预期提振投资者信心
异动解读 | 业绩超预期,Guardant Health盘前大涨20.73%
异动解读 · 2025-10-30
异动解读 | 业绩超预期,Guardant Health盘前大涨20.73%
异动解读 | 财报超预期,Guardant Health夜盘大涨21.77%
异动解读 · 2025-10-30
异动解读 | 财报超预期,Guardant Health夜盘大涨21.77%
异动解读 | 业绩超预期,Guardant Health盘后大涨11.11%
异动解读 · 2025-10-30
异动解读 | 业绩超预期,Guardant Health盘后大涨11.11%
Guardant Health 第三季度调整后每股亏损 USD -0.39,超出 IBES 预期 USD -0.76
投资观察 · 2025-10-30
Guardant Health 第三季度调整后每股亏损 USD -0.39,超出 IBES 预期 USD -0.76
Guardant Health与Zephyr AI宣布合作,以解锁药物反应预测和生物标志物洞察
美股速递 · 2025-10-27
Guardant Health与Zephyr AI宣布合作,以解锁药物反应预测和生物标志物洞察
加载更多
公司概况
公司名称:
Guardant Health Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Guardant Health, Inc.于2011年12月在特拉华州注册成立。该公司是一家领先的精密肿瘤学公司,致力于通过使用其专有血液测试,大量数据集和高级分析来帮助全球征服癌症。他们利用先进的血液和组织检测、真实世界数据和人工智能分析,提供关于疾病驱动因素的关键见解,从而变革患者护理。他们的检测有助于改善各个阶段的治疗效果,包括早期癌症筛查、早期癌症复发监测以及晚期癌症患者的治疗方案选择。
发行价格:
--
{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":85.18,"timestamp":1774036800000,"preClose":89.08,"halted":0,"volume":2401241,"hourTrading":{"tag":"盘后","latestPrice":86.84,"preClose":85.18,"latestTime":"19:59 EDT","volume":196827,"amount":16766395.9745,"timestamp":1774051181364,"change":1.66,"changeRate":0.019488,"amplitude":0.019488},"delay":0,"changeRate":-0.04378087112707669,"floatShares":126000000,"shares":131170441,"eps":-3.320281,"marketStatus":"已收盘","change":-3.9,"latestTime":"03-20 16:00:00 EDT","open":88.74,"high":89.11,"low":84.415,"amount":205579870.98641,"amplitude":0.052705,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.320281,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":89.08,"preHourTrading":{"tag":"盘前","latestPrice":88.43,"preClose":89.08,"latestTime":"09:29 EDT","volume":532,"amount":47139.57038,"timestamp":1774013399999,"change":-0.65,"changeRate":-0.007297,"amplitude":0.016165},"postHourTrading":{"tag":"盘后","latestPrice":86.84,"preClose":85.18,"latestTime":"19:59 EDT","volume":196827,"amount":16766395.9745,"timestamp":1774051181364,"change":1.66,"changeRate":0.019488,"amplitude":0.019488},"volumeRatio":1.4954,"impliedVol":0.6294,"impliedVolPercentile":0.5538},"requestUrl":"/m/hq/s/GH","defaultTab":"news","newsList":[{"id":"1160113114","title":"Guardant Health携手宏利在亚洲多市场推出Shield多癌种检测产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1160113114","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160113114?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664512,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.与宏利达成合作,正式在亚洲多个市场推出其创新产品——Shield多癌种早期检测测试。\n此次合作标志着Guardant Health在扩大其癌症筛查技术全球可及性方面迈出重要一步。通过利用Guardant Health先进的液体活检技术,Shield测试旨在通过简单血液样本实现对多种癌症类型的早期筛查。\n这一举措有望为亚洲地区患者提供更便捷、高效的癌症早期检测方案,从而提升癌症防治水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4196","GH","BK4588","BK4585","BK4551"],"gpt_icon":0},{"id":"1120663348","title":"宏利金融与Guardant Health达成独家合作,将Shield多癌种早筛检测引入亚洲市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1120663348","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120663348?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:01","pubTimestamp":1773630071,"startTime":"0","endTime":"0","summary":"宏利金融宣布与Guardant Health Inc.达成独家合作伙伴关系,双方将共同向亚洲地区客户推广Shield多癌种早期检测服务。此次合作旨在通过前沿的癌症筛查技术,为亚洲客户提供更全面的健康管理解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","GH","BK4196","BK4535","BK4551"],"gpt_icon":0},{"id":"1185436235","title":"财报前瞻|Guardant Health Inc.营收预计强劲增长,机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1185436235","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185436235?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:24","pubTimestamp":1770863073,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.将于2026年02月19日发布业绩,市场共识预计营收延续高增,亏损率收窄,核心产品渗透扩大成看点。公司目前主营业务亮点在于肿瘤学检测业务,受益于Guardant360与TissueNext在医院端与生物制药客户渗透,带动流水扩大。来自机构的最新观点更偏向看多阵营,占比高于看空观点。某些华尔街机构指出,“随着生物制药合作订单的稳定落地与核心检测项目扩容,Guardant Health Inc.的收入增长确定性较强,若指引印证高增与费用纪律,股价具备进一步修复空间。”","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Guardant Health Inc.营收预计强劲增长,机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"gpt_icon":0},{"id":"2609549637","title":"Guardant Health, Inc.涨2.82% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2609549637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609549637?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:35","pubTimestamp":1770388511,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日22时35分,Guardant Health, Inc.股票出现波动,股价快速拉升2.82%。Guardant Health, Inc.股票所在的生命科学行业中,整体涨幅为0.19%。其相关个股中,Ispecimen Inc.、Inotiv, Inc.、Personalis, Inc.涨幅较大,Ispecimen Inc.、Xwell, Inc.、Bioaffinity Technologies, Inc.较为活跃,换手率分别为91.58%、0.54%、0.19%,振幅较大的相关个股有Xwell, Inc.、Ispecimen Inc.、Check-Cap Ltd.,振幅分别为10.42%、10.29%、5.66%。Guardant Health, Inc.公司简介:总部位于加州红木城的Guardant Health是临床和研究用液体癌症检测的领导者。2021年,Guardant推出了Reveal,这是一种与肿瘤无关的分子残留疾病测试。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206223511a6dc0cb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206223511a6dc0cb0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GH","BK4585","BK4535","BK4588","BK4551","BK4196"],"gpt_icon":0},{"id":"2606246128","title":"维升药业隆培生长激素获批:1年长高11厘米,百亿市场格局生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246128","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606246128?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:13","pubTimestamp":1769436796,"startTime":"0","endTime":"0","summary":"1月26日,国家药品监督管理局(NMPA)正式批准维升药业(2561.HK)的核心产品——隆培生长激素注射液上市,该产品用于治疗儿童生长激素缺乏症(PGHD)。这款每周注射一次的长效生长激素,是国内首个且唯一经三期临床试验证实,其疗效优于日制剂的产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601263631011723.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601263631011723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GH","BK4585","BK4535","BK4588","BK4551","BK4196"],"gpt_icon":0},{"id":"1191355671","title":"Guardant Health公司Guardant360® Cdx获FDA批准 作为Braftovi®(Encorafenib)联合疗法在BRAF V600E突变转移性结直肠癌患者中的伴随诊断","url":"https://stock-news.laohu8.com/highlight/detail?id=1191355671","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191355671?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:07","pubTimestamp":1769087239,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已正式批准Guardant Health公司旗下液体活检产品Guardant360 Cdx,将其作为Braftovi联合疗法用于BRAF V600E突变型转移性结直肠癌患者的伴随诊断工具。Guardant360 Cdx作为一种基于血液的检测方法,能够通过简单抽血即可识别出适合接受靶向治疗的患者群体,为传统组织活检提供了一种微创替代方案。此次获批意味着,临床医生现在可以依据该检测结果,为携带BRAF V600E突变的转移性结直肠癌患者制定包含Braftovi的个性化联合治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","GH","BK4196","BK4535","BK4551"],"gpt_icon":0},{"id":"1124929599","title":"Guardant Health与Trial Library达成合作,提升美国癌症临床试验的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1124929599","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124929599?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:06","pubTimestamp":1765458406,"startTime":"0","endTime":"0","summary":"Guardant Health与Trial Library达成合作,提升美国癌症临床试验的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4551","BK4585","BK4588","BK4535","GH"],"gpt_icon":0},{"id":"1176561683","title":"Guardant Health 拟发行 3 亿美元可转换高级票据,到期时间为2033年","url":"https://stock-news.laohu8.com/highlight/detail?id=1176561683","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176561683?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:40","pubTimestamp":1763570401,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. :: Guardant Health 拟发行 3 亿美元的可转换高级票据,到期时间为2033年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","GH","BK4535","BK4196","BK4551"],"gpt_icon":0},{"id":"1140042890","title":"Guardant Health:肿瘤信号上升使疾病进展早至18个月,平均提前时间为2.3个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1140042890","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140042890?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:07","pubTimestamp":1762434465,"startTime":"0","endTime":"0","summary":"Guardant Health:肿瘤信号上升使疾病进展早至18个月,平均提前时间为2.3个月","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4551","BK4196","BK4585","BK4535","BK4588"],"gpt_icon":0},{"id":"1122589719","title":"Guardant Health:肿瘤信号减少超过98%的患者获得了显著益处","url":"https://stock-news.laohu8.com/highlight/detail?id=1122589719","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122589719?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:07","pubTimestamp":1762434460,"startTime":"0","endTime":"0","summary":"Guardant Health:肿瘤信号减少超过98%的患者获得了显著益处","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4535","GH","BK4196","BK4585","BK4551"],"gpt_icon":0},{"id":"1197091170","title":"异动解读 | Guardant Health股价盘中大跌8.77%,6.5亿美元融资计划引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1197091170","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197091170?lang=zh_cn&edition=full","pubTime":"2025-11-05 23:46","pubTimestamp":1762357612,"startTime":"0","endTime":"0","summary":"精准肿瘤学公司Guardant Health今日盘中大跌8.77%,延续了昨日夜间和今日盘前的跌势。这一显著跌幅主要源于公司最新宣布的大规模融资计划。据悉,Guardant Health于昨日收盘后宣布了一项重大融资计划。公司拟发行3亿美元的新股,同时还将非公开发行3.5亿美元、2033年到期的0%可转换债券。公司表示,此次融资所得将用于一般企业用途,包括回购部分2027年到期的0%可转换债券,以及潜在的互补产品和技术收购。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"gpt_icon":0},{"id":"1145268630","title":"异动解读 | Guardant Health股价盘前大跌6.15%,新股发行和可转债计划引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1145268630","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145268630?lang=zh_cn&edition=full","pubTime":"2025-11-05 17:46","pubTimestamp":1762336011,"startTime":"0","endTime":"0","summary":"周三盘前,精准肿瘤学公司Guardant Health股价大跌6.15%,延续了周二夜间交易时的跌势。这一显著跌幅主要源于公司最新宣布的大规模融资计划。据悉,Guardant Health于周二收盘后宣布了一项重大融资计划。公司表示,此次融资所得将用于一般企业用途,包括回购部分2027年到期的0%可转换债券,以及潜在的互补产品和技术收购。值得注意的是,尽管短期内股价承压,但Guardant Health的长期表现仍然强劲。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"gpt_icon":0},{"id":"1196560654","title":"异动解读 | Guardant Health夜盘大跌7.59%,新股和可转债发行计划引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1196560654","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196560654?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:15","pubTimestamp":1762305304,"startTime":"0","endTime":"0","summary":"精准肿瘤学公司Guardant Health在夜盘交易中股价大幅下跌7.59%,引发市场广泛关注。这一显著跌幅主要源于公司最新宣布的大规模融资计划。据悉,Guardant Health计划发行2.5亿美元的新股,同时非公开发行3亿美元、2033年到期的可转换债券。公司表示,此次融资所得将用于一般企业用途,包括回购部分2027年到期的0%可转换债券,以及潜在的互补产品和技术收购。尽管短期内股价承压,但Guardant Health的长期表现仍然强劲。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"gpt_icon":0},{"id":"1129896298","title":"异动解读 | Guardant Health盘后大跌8.55%,拟发行新股和可转债","url":"https://stock-news.laohu8.com/highlight/detail?id=1129896298","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129896298?lang=zh_cn&edition=full","pubTime":"2025-11-05 06:32","pubTimestamp":1762295540,"startTime":"0","endTime":"0","summary":"周二盘后交易中,精准肿瘤学公司Guardant Health股价大幅下跌8.55%,引发投资者关注。据悉,Guardant Health宣布了一项重大融资计划。公司拟发行2.5亿美元的新股,同时还将非公开发行3亿美元2033年到期的可转换债券。公司表示,此次融资所得将用于一般企业用途,包括回购部分2027年到期的0%可转换债券,以及潜在的互补产品和技术收购。值得注意的是,Guardant Health目前已发行股票约1.26亿股,市值约124亿美元。尽管公司股价在盘后出现大幅下跌,但Guardant Health的长期表现依然强劲。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"gpt_icon":0},{"id":"1137640606","title":"异动解读 | 盘中飙升27.45%,Guardant Health财报超预期提振投资者信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1137640606","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137640606?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:03","pubTimestamp":1761833006,"startTime":"0","endTime":"0","summary":"癌症检测公司Guardant Health周四盘中股价大涨27.45%,创下近期新高。这一显著涨幅主要源于公司发布的第三季度财报远超市场预期,极大提振了投资者信心。根据公司公布的财报显示,Guardant Health第三季度收入达到2.652亿美元,明显高于分析师预期的2.357亿美元。受此利好消息影响,多家券商纷纷上调了Guardant Health的目标价。分析师普遍认为,Guardant Health在癌症液体活检技术领域的领先地位,以及其业务的持续改善,将为公司未来的增长提供强劲动力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"29d42f0ac458daa518aec51f8817eeb0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"gpt_icon":0},{"id":"1139818900","title":"异动解读 | 业绩超预期,Guardant Health盘前大涨20.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139818900","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139818900?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:10","pubTimestamp":1761811821,"startTime":"0","endTime":"0","summary":"癌症检测公司Guardant Health Inc.周四盘前股价大涨20.73%,引发市场广泛关注。这一显著涨幅主要源于公司发布的第三季度财报远超市场预期。根据公司公布的财报显示,Guardant Health第三季度收入达到2.652亿美元,明显高于分析师预期的2.357亿美元。Guardant Health是一家专注于癌症检测和诊断的生物科技公司,其液体活检技术在市场上备受关注。此外,Canaccord Genuity将公司的目标价从75美元上调至100美元,进一步提振了投资者信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"29d42f0ac458daa518aec51f8817eeb0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"gpt_icon":1},{"id":"1174423868","title":"异动解读 | 财报超预期,Guardant Health夜盘大涨21.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174423868","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174423868?lang=zh_cn&edition=full","pubTime":"2025-10-30 08:30","pubTimestamp":1761784244,"startTime":"0","endTime":"0","summary":"周三夜盘,癌症检测公司Guardant Health Inc.股价大涨21.77%,引发市场广泛关注。这一显著涨幅主要源于公司发布的第三季度财报远超市场预期。根据公司公布的财报显示,Guardant Health第三季度收入达到2.652亿美元,明显高于分析师预期的2.357亿美元。Guardant Health是一家专注于癌症检测和诊断的生物科技公司,其液体活检技术在市场上备受关注。此次超预期的财报结果不仅显示了公司业务的显著改善,也可能反映出其在癌症诊断领域的市场份额正在扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"29d42f0ac458daa518aec51f8817eeb0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"gpt_icon":1},{"id":"1160061473","title":"异动解读 | 业绩超预期,Guardant Health盘后大涨11.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160061473","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160061473?lang=zh_cn&edition=full","pubTime":"2025-10-30 04:34","pubTimestamp":1761770042,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.今日盘后股价大涨11.11%,引起投资者广泛关注。这一显著涨幅主要源于公司发布的第三季度财报优于市场预期。根据公司公布的财报显示,Guardant Health第三季度收入达到2.652亿美元,超过分析师预期的2.357亿美元。Guardant Health是一家专注于癌症检测和诊断的生物科技公司,其液体活检技术在市场上备受关注。此次超预期的财报结果不仅显示了公司业务的强劲增长,也可能反映出其在癌症诊断领域的市场份额正在扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"gpt_icon":0},{"id":"1176722378","title":"Guardant Health 第三季度调整后每股亏损 USD -0.39,超出 IBES 预期 USD -0.76","url":"https://stock-news.laohu8.com/highlight/detail?id=1176722378","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176722378?lang=zh_cn&edition=full","pubTime":"2025-10-30 04:26","pubTimestamp":1761769600,"startTime":"0","endTime":"0","summary":"10月29日 - Guardant Health 第三季度收入为 2.652 亿美元,而 IBES 预期为 2.357 亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4585","BK4196","BK4588","GH","BK4535"],"gpt_icon":0},{"id":"1153214292","title":"Guardant Health与Zephyr AI宣布合作,以解锁药物反应预测和生物标志物洞察","url":"https://stock-news.laohu8.com/highlight/detail?id=1153214292","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153214292?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:07","pubTimestamp":1761566829,"startTime":"0","endTime":"0","summary":"Guardant Health与Zephyr AI宣布合作,以解锁药物反应预测和生物标志物洞察","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","GH","BK4535","BK4196","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":0.0602},{"period":"1month","weight":-0.1683},{"period":"3month","weight":-0.1069},{"period":"6month","weight":0.506},{"period":"1year","weight":0.9265},{"period":"ytd","weight":-0.1279}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Guardant Health, Inc.于2011年12月在特拉华州注册成立。该公司是一家领先的精密肿瘤学公司,致力于通过使用其专有血液测试,大量数据集和高级分析来帮助全球征服癌症。他们利用先进的血液和组织检测、真实世界数据和人工智能分析,提供关于疾病驱动因素的关键见解,从而变革患者护理。他们的检测有助于改善各个阶段的治疗效果,包括早期癌症筛查、早期癌症复发监测以及晚期癌症患者的治疗方案选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027188},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.017651},{"month":5,"riseRate":0.571429,"avgChangeRate":0.065461},{"month":6,"riseRate":0.714286,"avgChangeRate":0.081894},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Guardant Health Inc.(GH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Guardant Health Inc.(GH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}